Skip to main content

News from our members

On this page, you will find the latest news from the cluster's members!

• 03/06/20 - Hyloris Pharma prépare son introduction sur Euronext Bruxelles  (Only available in french)


La biotech liégeoise créée par Stijn Van Rompay vient de dévoiler son intention de se faire coter sur Euronext Bruxelles. Une opération qui devrait être finalisée début juillet. Read more

• 01/06/20 - Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program


Celyad today announced updates from the company’s allogeneic programs, including additional data from the Phase 1 alloSHRINK trial evaluating the T cell receptor (TCR) inhibitory molecule (TIM)-based, non-gene edited allogeneic CAR-T candidate, CYAD‑101, for the treatment of metastatic colorectal cancer (mCRC), and the company’s short hairpin RNA (shRNA) platform underpinning the next-generation, non-gene edited CYAD-200 series of CAR-T candidates. Read more

• 28/05/20 - GSK va produire un milliard de doses d'adjuvants pour les vaccins Covid-19


Le géant pharmaceutique britannique a indiqué qu'il entendait produire un milliard de doses d'adjuvants pour les vaccins Covid-19 en 2021. La fabrication aura lieu sur des sites en Europe et en Amérique du Nord. Read more

• 28/05/20 - Mithra Signs License and Supply Agreement with Mayne Pharma for Commercialization of Estelle in Australia


Mithra today announces it has entered into an exclusive 20-year license and supply agreement with Mayne Pharma Group Limited (“Mayne”) for the commercialization of its combined oral contraceptive E4/DRSP (Estelle) in Australia. Read more

• 28/05/20 - Oncodesign establishes strategic alliance with HitGen to strengthen its integrated drug discovery service


Oncodesign announces that it has formed a new strategic alliance with HitGen, a Chinese biotech company. This partnership complements Oncodesign’s technological platforms and enables the identification of novel hits for challenging biological targets. It also strengthens its Integrated Drug Discovery Service (IDDS) offer, known as DRIVE™ (DRug Integrative discoVEry). Read more

• 25/05/20 - NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product


With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene’s lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3. Read more

• 25/05/20 - Mithra Launches a Research Programme on Estetrol's Effect in Covid-19 Treatment. 


Mithra today announces its intention to launch a Phase II study program to assess the potential beneficial effect of Estetrol (E4) on Covid-19 infection. E4 is a naturally occurring estrogen produced by the liver of the human fetus, passing in maternal blood at relatively high levels during pregnancy. Read more

• 20/05/20 - Mithra and Searchlight Pharma Announce Filing of New Drug Submission for Estelle® in Canada


Mithra and Searchlight Pharma announced today that Health Canada has accepted Searchlight Pharma’s New Drug Submission (“NDS”) for a novel combined oral contraceptive (COC) product. Read more

• 18/05/20 - Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study


BONE THERAPEUTICS today announces it has commenced treating the first patients for the pivotal JTA-004 phase III clinical study in Hong Kong SAR. Read more

• 18/05/20 - Miracor Medical - Effect of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size in anterior STEMI: PiCSO in ACS study

logo miracor

The aim of this clinical research was to investigate the effects of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size at 5 days after primary percutaneous coronary intervention (pPCI) in patients with ST-segment elevation myocardial infarction (STEMI). Read more

• 18/05/20 - The Walloon government has labeled NeuroPath’s R&I project. NeuroInsights joins a portfolio of 49 R&I projects


NeuroInsights provides a Digital Health Platform to connect the daily living of the patient with the interdisciplinary team of care providers and clinicians. Read more

• 14/05/20 - Exyte & Univercells Technologies combine forces for rapid deployment of vaccine production plants in the wake of the COVID-19 pandemic


The combined offer will enable users to rapidly deploy prefabricated GMP vaccine manufacturing facilities in response to new disease outbreaks. Read more

• 14/05/20 - Une première mondiale chirurgicale avec des implants en os synthétique développés à Liège

Cerhum3D side

C’est une technologie développée par la PME liégeoise Cerhum avec l’expertise de 3DSide qui a permis de concevoir cet implant inédit. Read more

• 12/05/20 - IMI announces COVID projects, boosts funding pot to EUR 72 million. The Innovative Medicines Initiative has provisionally selected 8 projects for funding from its fast-track Call for proposals on coronavirus diagnostics and treatments. One of the projects, Dragon (Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics) will be lead by Oncoradiomics


The DRAGON project will apply artificial intelligence and machine learning to deliver a decision support system for improved and more rapid diagnosis and prognosis. Citizens and patients will be involved in the development of the system. Read more

• 13/05/20 - Résultats encourageants pour Novadip dans la reconstruction osseuse


Plusieurs patients suivis par la biotech wallonne dans la cadre d'une étude clinique exploratoire évoluent vers une régénération osseuse complète six mois seulement après avoir été implantés. Read more

• 07/05/20 - Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15.0 million committed, providing runway into Q2 2021


The company today announces that it has received EUR 4.0 million. This enables Bone Therapeutics’ bond investors to be repaid in the company’s shares, with a conversion price of EUR 7.0 per share. This additional EUR 4.0 million financing has been achieved a week after the EUR 11.0 million financing round. Read more

• 07/05/20 - Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights


Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced an update on operational developments for the first quarter ended March 31, 2020. Read more

• 06/05/20 - Celyad Appoints Seasoned Industry Executives to Board of Directors


Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that Dr. Maria Koehler and Mr. Dominic Piscitelli have been appointed as independent members to its Board of Directors, effective as of March 24 and May 6, respectively. Read more

• 05/05/20 -  Launch of Univercells Technologies for intensified, automated technologies 


Univercells Technologies, a global provider of next-generation bioprocess technologies, launches today.  Under this new brand, the company will focus on the commercialization of the product portfolio and will explore new technology developments to expand its position in the cell and gene therapy market. Read More

• 05/05/20 - Mithra and Gynial Sign Commercialization Agreement for Myring™ in Switzerland


Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement (LSA) with Gynial GmbH for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland. Read more

• 30/04/20 - La biotech Hyloris attire de nouveaux investisseurs flamands (Only available in french)


La biotech liégeoise Hyloris a levé 15 millions d'euros pour développer ses médicaments reformulés. En savoir plus

• 30/04/20 - IRE supplies a first commercial batch of LEU-based Mo-99


The Institute for radioelements (IRE), one of the leaders in the production of Molybdenum-99 (Mo-99), the most widely used radio-isotope in nuclear medicine for diagnosis, announced today that the company produced its first commercial Mo-99 Low Enriched Uranium (LEU) batch for the US market. Read more

• 29/04/20 - Bone Therapeutics secures EUR 11.0 million financing


Bone Therapeutics today announces that it secured EUR 11.0 million financing. The financing will be used to advance both of its key assets, ALLOB and JTA-004, through late stage clinical development. Read more

• 28/04/20 - Coronavirus en Belgique: Univercells se prépare à produire un vaccin (Only available in french)


Un vaccin contre le coronavirus Covid-19 est attendu avec grande impatience. L'entreprise de Nivelles, Univercells, se prépare d'ailleurs à produire ce vaccin grâce à un système de conteneurs. En savoir plus

• 28/04/20 - Les tests rapides du liégeois ZenTech validés par l'agence fédérale des médicaments (Only available in french)


Les tests de dépistage du Covid-19 de la société liégeoise ZenTech viennent d’obtenir la certification de l’agence fédérale des médicaments (AFPMS). Ils peuvent donc désormais être commercialisés en Belgique. En savoir plus

• 27/04/20 - Brussels South Charleroi BioPark announces strong Q1 2020 performance


Despite the Coronavirus crisis, Brussels South Charleroi BioPark, which gathers 70+ biotech and biopharma players, booked a historically strong performance in the first quarter of 2020. Read more

• 24/04/20 - BioCair transports COVID-19 related protective equipment


Biocair has recently managed several urgent large-scale shipments of COVID-19 related protective equipment. The specialist logistics company is also supporting many companies and agencies with the swift transportation of testing kits, diagnostic specimens and medical devices. Read more

• 24/04/20 - Mithra Obtains a Capital Commitment Agreement of EUR 50 Million from Partner LDA Capital


Mithra today announces that it has entered into a capital commitment agreement with LDA Capital Limited, a Los Angeles based global investment group with expertise in cross border transactions in life science sector. Read more

• 23/04/20 - ReiThera, Leukocare and Univercells announce fast-track development of a COVID-19 vaccine


The vaccine candidate is expected to enter clinical trials during summer 2020 with large-scale vaccine production planned to start soon after. Read more

• 23/04/20 - Solution SalamanderU et solidfog technologies pour la décontamination de masques ffp2 (Only available in french)


Les deux entreprises ont collaboré pour fournir une solution opérationnelle simple et robuste pour la décontamination de masques FFP2 en grande quantité et à installer directement au sein du milieu hospitalier. En savoir plus / Infographie

• 21/04/20 - Le spécialiste wallon de l'hygiène Realco/OneLife tourne à nouveau à plein régime. (Only available in french)


Le site de Louvain-La-Neuve de Realco avait été en partie détruit par un incendie début janvier. L’entreprise de Louvain-La-Neuve estime avoir des solutions à proposer pour le déconfinement. En savoir plus

• 17/04/20 - Walloon company ZenTech launches its production of serological tests (Only available in french)


Liège-based bio-tech company ZenTech launched its own production line for rapid screening tests for Covid-19 on Thursday morning. These serological tests detect antibodies that appear after a coronavirus infection. Read more

• 16/04/20 - Mayne Pharma Submits New Drug Application For E4/DRSP to the FDA


Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) today announced that Mayne Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for E4/DRSP, a combined oral contraceptive indicated for the prevention of pregnancy in women. Read more

• 14/04/20 - GSK et Sanofi s'unissent pour développer un vaccin qui aura des accents belges (Only available in french)


Les deux géants pharmaceutiques GSK et Sanofi espèrent lancer les essais cliniques au second semestre 2020 pour commercialiser un vaccin contre le Covid-19 un an plus tard. Le site belge de Rixensart de GSK sera impliqué dans les recherches notamment via sa technologie des adjuvants. Read more

• 08/04/20 - Orgenesis Announces Joint Venture Agreement with RevaTis 


The goal of the JV is to advance the development of autologous therapies, including in-licensed therapies through Orgenesis’s partners, utilizing and banking muscle-derived mesenchymal stem cells (mdMSC) as a source of exosomes and other cellular products. Read more

• 02/04/20 - Mithra Announces Commercial Launch of Myring™ in Germany, the biggest market in Europe.


Mithra, a company dedicated to Women’s Health announced the commercial launch of Myring™ in Germany, which is the largest European market and the second worldwide in terms of sales volume. Read more

• 01/04/20 - iTeos Therapeutics closes $125 Million Series B2 Financing!


iTeos Therapeutics, biotech company in our Walloon ecosystem, raised $125 million to support the clinical development of its two innovative cancer immunotherapy programs. Read more

You have news to share? Contact us!